Straits Times Index
3,338.94 -9.93 (-0.30%) S&P 500
5,266.80 -16.60 (-0.31%) Dow
38,549.13 -21.90 (-0.06%) Nasdaq
16,777.17 -51.50 (-0.31%) Bitcoin USD
70,742.03 +1,790.79 (+2.60%) CMC Crypto 200
1,476.98 +29.83 (+2.06%)
Basilea Pharmaceutica AG (BSLN.SW)
- Zacks
Basilea Pharmaceutica (BPMUF) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Basilea Pharmaceutica (BPMUF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
Allschwil, Switzerland, May 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s Ch
- GlobeNewswire
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
Allschwil, Switzerland, May 03, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that scientific presentations with new data on its antibiotic ceftobiprole (Zevtera®) have been presented at ESCMID Global 2024, the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, which took place from April 27 to 30, 2024
